95 -10 (84) 2025 - Ismailova J.A., Alimbetova G.Е. - BIOMARKER-GUIDED NUTRITION: THE ROLE OF METABOLOMICS IN DESIGNING PERSONALIZED DIETS FOR CHRONIC CONDITIONS

BIOMARKER-GUIDED NUTRITION: THE ROLE OF METABOLOMICS IN DESIGNING PERSONALIZED DIETS FOR CHRONIC CONDITIONS

Ismailova J.A. - "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM

Alimbetova G.Е. - "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM

Resume

This study presents an analysis of metabolomic profiles in patients with type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and their combination. Data from 200 patients revealed significant differences in the levels of branched-chain amino acids (BCAAs), oxidative stress markers, microbiota-associated metabolites, and short-chain fatty acids (SCFAs) compared to the control group. Personalized dietary therapy based on metabolomic indicators led to significant improvements in clinical and biochemical parameters, particularly in patients with combined pathology. The findings support the effectiveness of a metabolomics-driven approach for individualizing nutrition and reducing cardiometabolic risk.

Keywords: metabolomics; type 2 diabetes mellitus; cardiovascular diseases; personalized nutritional recommendations; short-chain fatty acids (SCFAs); BCAAs; oxidative stress; gut microbiota.

First page

543

Last page

549

For citation:Ismailova J.A., Alimbetova G.Е. - BIOMARKER-GUIDED NUTRITION: THE ROLE OF METABOLOMICS IN DESIGNING PERSONALIZED DIETS FOR CHRONIC CONDITIONS//New Day in Medicine 10(84)2025 543-549 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом Под редакцией И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. – 12-й выпуск. – М.; 2025.
2. Волкова Е.А., Малыгина О.Ф. Сахарный диабет и сердечно-сосудистые заболевания. Актуальный подход к модификации образа жизни и лечению пациентов с сахарным диабетом 2-го типа. Consilium Medicum. 2019; 21 (1): 74-80. DOI: 10.26442/20751753.2019.1.190273.
3. Adamski, J. (2016). Key elements of metabolomics in the study of biomarkers of diabetes. Diabetologia 2016;59:2497–2502. doi: 10.1007/s00125-016-4044-y
4. Al-Goblan, A. S., Al-Alfi, M. A., and Khan, M. Z. (2014). Mechanism linking diabetes mellitus and obesity. Diabetes Metab. Syndr. Obes.2014;7:587–591. doi: 10.2147/dmso.s67400
5. Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, Romiti GF. Risk ofcardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2022;29(6):938–46. https://doi.org/10.1093/eurjpc/zwab212.
6. Castillo-Leon E, Connelly MA, Konomi JV, Caltharp S, Cleeton R, Vos MB. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis. Pediatr Obes 2020;15(9):e12648. https://doi.org/10.1111/ ijpo.12648.
7. Dahabiyeh, L. A., Malkawi, A. K., Wang, X., Colak, D., Mujamammi, A. H., Sabi, E. M., et al. (2020). Dexamethasone-Induced Perturbations in Tissue Metabolomics Revealed by Chemical Isotope Labeling LC-MS analysis. Metabolites 10:42. doi: 10.3390/metabo10020042
8. De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Masciana` G, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes 2022;46(3):486–93. https://doi.org/10.1038/s41366-021-01015-w.
9. Jacob, M., Gu, X., Luo, X., Al-Mousa, H., Arnaout, R., Al-Saud, B., et al. (2019a). Metabolomics Distinguishes DOCK8 Deficiency from Atopic Dermatitis: Towards a Biomarker Discovery. Metabolites 9, 274. doi: 10.3390/metabo9110274
10. Karami S, Poustchi H, Sarmadi N, Radmard AR, Ali Yari F, Pakdel A, Shabani P. Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. Diabetol Metab Syndrome 2021;13(1):121. https://doi.org/10.1186/s13098-021-00741-5

    file

    download